CN102321587A - 肺癌药物筛选细胞株的建立 - Google Patents
肺癌药物筛选细胞株的建立 Download PDFInfo
- Publication number
- CN102321587A CN102321587A CN201110245360A CN201110245360A CN102321587A CN 102321587 A CN102321587 A CN 102321587A CN 201110245360 A CN201110245360 A CN 201110245360A CN 201110245360 A CN201110245360 A CN 201110245360A CN 102321587 A CN102321587 A CN 102321587A
- Authority
- CN
- China
- Prior art keywords
- cell line
- cell
- lung carcinoma
- gene
- carcinoma cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 83
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 50
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 50
- 239000003560 cancer drug Substances 0.000 title claims abstract description 9
- 238000010276 construction Methods 0.000 title abstract 2
- 238000007877 drug screening Methods 0.000 title description 2
- 238000012216 screening Methods 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 241000700605 Viruses Species 0.000 claims description 35
- 201000005296 lung carcinoma Diseases 0.000 claims description 33
- 108700008625 Reporter Genes Proteins 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 28
- 239000003242 anti bacterial agent Substances 0.000 claims description 25
- 229940088710 antibiotic agent Drugs 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 238000001890 transfection Methods 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 15
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 9
- 239000004098 Tetracycline Substances 0.000 claims description 9
- 229960002180 tetracycline Drugs 0.000 claims description 9
- 229930101283 tetracycline Natural products 0.000 claims description 9
- 235000019364 tetracycline Nutrition 0.000 claims description 9
- 150000003522 tetracyclines Chemical class 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 99
- 230000010354 integration Effects 0.000 abstract description 7
- 230000002068 genetic effect Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 28
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229950010131 puromycin Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 101000672034 Bacillus sp. (strain GL1) Unsaturated glucuronyl hydrolase Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110245360.4A CN102321587B (zh) | 2011-08-25 | 2011-08-25 | 肺癌药物筛选细胞株的建立 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110245360.4A CN102321587B (zh) | 2011-08-25 | 2011-08-25 | 肺癌药物筛选细胞株的建立 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102321587A true CN102321587A (zh) | 2012-01-18 |
CN102321587B CN102321587B (zh) | 2015-11-18 |
Family
ID=45449423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110245360.4A Active CN102321587B (zh) | 2011-08-25 | 2011-08-25 | 肺癌药物筛选细胞株的建立 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102321587B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104130977A (zh) * | 2014-08-05 | 2014-11-05 | 中国科学院昆明动物研究所 | 一种抗肿瘤药物筛选细胞模型及其应用 |
CN105400740A (zh) * | 2015-10-30 | 2016-03-16 | 温州医科大学附属第一医院 | 人肺癌耐百草枯细胞株的建立方法及应用 |
CN105754950A (zh) * | 2016-04-23 | 2016-07-13 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型mcf-7-gfp及其应用方法 |
CN105925532A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型hbl-100-gfp及其应用方法 |
CN105925531A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型mda-mb-231-gfp及其应用方法 |
CN105925534A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型u87-mg-gfp及其应用方法 |
CN105925533A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型a549-gfp及其应用方法 |
CN108823170A (zh) * | 2018-06-28 | 2018-11-16 | 山西大学 | 一种基于蛋白质错误折叠的用于抗氧化药物筛选的细胞模型的构建方法 |
CN108913662A (zh) * | 2018-08-09 | 2018-11-30 | 爱克精医(北京)生物医药科技有限公司 | 一种肺癌功能性高通量用药筛选的方法 |
-
2011
- 2011-08-25 CN CN201110245360.4A patent/CN102321587B/zh active Active
Non-Patent Citations (3)
Title |
---|
IZUMI等: "HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication", 《PNAS》 * |
KNOBLACH等: "Human Cytomegalovirus IE1 Protein Elicits a Type II Interferon-Like Host Cell Response That Depends on Activated STAT1 but Not Interferon-c", 《PLOS PATHOGENS》 * |
RAZORENOVA等: "Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1", 《GENE》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104130977A (zh) * | 2014-08-05 | 2014-11-05 | 中国科学院昆明动物研究所 | 一种抗肿瘤药物筛选细胞模型及其应用 |
CN104130977B (zh) * | 2014-08-05 | 2017-06-13 | 中国科学院昆明动物研究所 | 一种抗肿瘤药物筛选细胞模型及其应用 |
CN105400740A (zh) * | 2015-10-30 | 2016-03-16 | 温州医科大学附属第一医院 | 人肺癌耐百草枯细胞株的建立方法及应用 |
CN105400740B (zh) * | 2015-10-30 | 2019-08-13 | 温州医科大学附属第一医院 | 人肺癌耐百草枯细胞株的建立方法及应用 |
CN105925533A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型a549-gfp及其应用方法 |
CN105925534A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型u87-mg-gfp及其应用方法 |
CN105925531A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型mda-mb-231-gfp及其应用方法 |
CN105925532A (zh) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型hbl-100-gfp及其应用方法 |
CN105754950A (zh) * | 2016-04-23 | 2016-07-13 | 同济大学苏州研究院 | 一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型mcf-7-gfp及其应用方法 |
CN108823170A (zh) * | 2018-06-28 | 2018-11-16 | 山西大学 | 一种基于蛋白质错误折叠的用于抗氧化药物筛选的细胞模型的构建方法 |
CN108823170B (zh) * | 2018-06-28 | 2021-07-02 | 山西大学 | 一种基于蛋白质错误折叠的用于抗氧化药物筛选的细胞模型的构建方法 |
CN108913662A (zh) * | 2018-08-09 | 2018-11-30 | 爱克精医(北京)生物医药科技有限公司 | 一种肺癌功能性高通量用药筛选的方法 |
CN108913662B (zh) * | 2018-08-09 | 2019-03-29 | 爱克精医(北京)生物医药科技有限公司 | 一种肺癌功能性高通量用药筛选的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102321587B (zh) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102321587B (zh) | 肺癌药物筛选细胞株的建立 | |
Berger et al. | A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1–derived lentiviral vectors | |
CN106801056A (zh) | 一种sgRNA及其构建的慢病毒载体和应用 | |
Ajuh et al. | Novel human polyomavirus noncoding control regions differ in bidirectional gene expression according to host cell, large T-antigen expression, and clinically occurring rearrangements | |
Abere et al. | Merkel cell polyomavirus encodes circular RNAs (circRNAs) enabling a dynamic circRNA/microRNA/mRNA regulatory network | |
CN106459976A (zh) | 提高细胞生产效率的miRNA | |
CN107190024A (zh) | 一种稳定表达ns1蛋白细胞株的构建方法 | |
JP2022043022A (ja) | レンチウイルスベクターのバイオ生産法 | |
EP3778880A1 (en) | Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells | |
CN107099495A (zh) | 一种用于哺乳动物细胞蛋白质递送工程菌株的构建方法及应用 | |
JP2022551219A (ja) | レンチウイルスベクターの製造方法および構築物 | |
López et al. | High-throughput fluorescence-based screen identifies the neuronal microRNA miR-124 as a positive regulator of alphavirus infection | |
CN110423782A (zh) | 一株Marc-145稳定细胞株的构建及应用 | |
CN114107311A (zh) | 参与猪传染性胃肠炎病毒感染的靶点及其应用 | |
WO2023072178A1 (en) | Methods for developing a cell line for producing virus in suspension cell culture | |
Selden et al. | Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes | |
Tang et al. | Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy | |
Göbel et al. | Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures | |
CN112011518A (zh) | 寨卡病毒zg01株反向遗传系统的构建及其应用 | |
Behiels et al. | High-level production of recombinant eukaryotic proteins from mammalian cells using lentivirus | |
CN108018302A (zh) | 一种高表达外源蛋白稳定细胞株的筛选方法 | |
Vamva et al. | An optimized measles virus glycoprotein-pseudotyped lentiviral vector production system to promote efficient transduction of human primary B cells | |
CN102229928B (zh) | 人rbbp6基因的小干扰rna及其应用 | |
CN102453698A (zh) | 悬浮培养传代细胞及利用其生产猪瘟疫苗的方法 | |
Elizalde et al. | Lentiviral vectors: key challenges and new developments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 200233, room 680, 619-21 Guiping Road, Shanghai, Xuhui District Patentee after: Shanghai Jikai gene Medical Technology Co.,Ltd. Address before: 201203, Pudong New Area hi tech park, Shanghai, Edison Road, No. 2, building 328 Patentee before: SHANGHAI GENECHEM Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231218 Address after: Room 805G, Building 5, No. 750 Linyuan Street, Zhujing Town, Jinshan District, Shanghai, 201500 Patentee after: Shanghai Jikai Biotechnology Co.,Ltd. Address before: Room 619-21, 680 Guiping Road, Xuhui District, Shanghai 200233 Patentee before: Shanghai Jikai gene Medical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |